Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, another oral therapy that was first approved by the Food and Drug Administration for treatment of T2D in adults in 2006 (14, 15). Here, DPP4 is linked to type 2 diabetes mellitus.